The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Adrenocortical Carcinoma Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. The causes of primary adrenocortical carcinoma are unknown. However adrenocortical carcinoma can also be secondary cancer. A secondary cancer is what happens when another form of cancer spreads to the adrenal glands. Adrenocortical carcinoma can occur at any age, but there is a bimodal distribution with a first peak at childhood between 1–6 years old and the second peak in the fourth to the fifth decade of life. During the past decade, collaborative efforts have been made to improve the ACC treatment.
The global Adrenocortical Carcinoma Treatment market size is expected to reach US$ 604.5 million by 2029, growing at a CAGR of 1.5% from 2023 to 2029. The market is mainly driven by the significant applications of Adrenocortical Carcinoma Treatment in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Clinics and Cancer Research Institutes, are propelling Adrenocortical Carcinoma Treatment market. Localized Adrenocortical Carcinoma, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Metastatic Adrenocortical Carcinoma segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Adrenocortical Carcinoma Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Adrenocortical Carcinoma Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Adrenocortical Carcinoma Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Adrenocortical Carcinoma Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Adrenocortical Carcinoma Treatment covered in this report include ArQule, EnGeneIC, Exelixis, Merck, Millendo Therapeutics and Orphagen Pharmaceuticals, etc.
The global Adrenocortical Carcinoma Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
ArQule
EnGeneIC
Exelixis
Merck
Millendo Therapeutics
Orphagen Pharmaceuticals
Global Adrenocortical Carcinoma Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Adrenocortical Carcinoma Treatment market, Segment by Type:
Localized Adrenocortical Carcinoma
Metastatic Adrenocortical Carcinoma
Global Adrenocortical Carcinoma Treatment market, by Application
Hospitals
Ambulatory Surgical Centers
Clinics
Cancer Research Institutes
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Adrenocortical Carcinoma Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. The causes of primary adrenocortical carcinoma are unknown. However adrenocortical carcinoma can also be secondary cancer. A secondary cancer is what happens when another form of cancer spreads to the adrenal glands. Adrenocortical carcinoma can occur at any age, but there is a bimodal distribution with a first peak at childhood between 1–6 years old and the second peak in the fourth to the fifth decade of life. During the past decade, collaborative efforts have been made to improve the ACC treatment.
The global Adrenocortical Carcinoma Treatment market size is expected to reach US$ 604.5 million by 2029, growing at a CAGR of 1.5% from 2023 to 2029. The market is mainly driven by the significant applications of Adrenocortical Carcinoma Treatment in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Clinics and Cancer Research Institutes, are propelling Adrenocortical Carcinoma Treatment market. Localized Adrenocortical Carcinoma, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Metastatic Adrenocortical Carcinoma segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Adrenocortical Carcinoma Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Adrenocortical Carcinoma Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Adrenocortical Carcinoma Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Adrenocortical Carcinoma Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Adrenocortical Carcinoma Treatment covered in this report include ArQule, EnGeneIC, Exelixis, Merck, Millendo Therapeutics and Orphagen Pharmaceuticals, etc.
The global Adrenocortical Carcinoma Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
ArQule
EnGeneIC
Exelixis
Merck
Millendo Therapeutics
Orphagen Pharmaceuticals
Global Adrenocortical Carcinoma Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Adrenocortical Carcinoma Treatment market, Segment by Type:
Localized Adrenocortical Carcinoma
Metastatic Adrenocortical Carcinoma
Global Adrenocortical Carcinoma Treatment market, by Application
Hospitals
Ambulatory Surgical Centers
Clinics
Cancer Research Institutes
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Adrenocortical Carcinoma Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Adrenocortical Carcinoma Treatment
1.1 Adrenocortical Carcinoma Treatment Market Overview
1.1.1 Adrenocortical Carcinoma Treatment Product Scope
1.1.2 Adrenocortical Carcinoma Treatment Market Status and Outlook
1.2 Global Adrenocortical Carcinoma Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Adrenocortical Carcinoma Treatment Market Size by Region (2018-2029)
1.4 Global Adrenocortical Carcinoma Treatment Historic Market Size by Region (2018-2023)
1.5 Global Adrenocortical Carcinoma Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Adrenocortical Carcinoma Treatment Market Size (2018-2029)
1.6.1 North America Adrenocortical Carcinoma Treatment Market Size (2018-2029)
1.6.2 Europe Adrenocortical Carcinoma Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Adrenocortical Carcinoma Treatment Market Size (2018-2029)
1.6.4 Latin America Adrenocortical Carcinoma Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Adrenocortical Carcinoma Treatment Market Size (2018-2029)
2 Adrenocortical Carcinoma Treatment Market by Type
2.1 Introduction
2.1.1 Localized Adrenocortical Carcinoma
2.1.2 Metastatic Adrenocortical Carcinoma
2.2 Global Adrenocortical Carcinoma Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Adrenocortical Carcinoma Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Adrenocortical Carcinoma Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Adrenocortical Carcinoma Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Adrenocortical Carcinoma Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Adrenocortical Carcinoma Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Adrenocortical Carcinoma Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Adrenocortical Carcinoma Treatment Revenue Breakdown by Type (2018-2029)
3 Adrenocortical Carcinoma Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Clinics
3.1.4 Cancer Research Institutes
3.2 Global Adrenocortical Carcinoma Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Adrenocortical Carcinoma Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Adrenocortical Carcinoma Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Adrenocortical Carcinoma Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Adrenocortical Carcinoma Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Adrenocortical Carcinoma Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Adrenocortical Carcinoma Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Adrenocortical Carcinoma Treatment Revenue Breakdown by Application (2018-2029)
4 Adrenocortical Carcinoma Treatment Competition Analysis by Players
4.1 Global Adrenocortical Carcinoma Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Adrenocortical Carcinoma Treatment as of 2022)
4.3 Date of Key Players Enter into Adrenocortical Carcinoma Treatment Market
4.4 Global Top Players Adrenocortical Carcinoma Treatment Headquarters and Area Served
4.5 Key Players Adrenocortical Carcinoma Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Adrenocortical Carcinoma Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 ArQule
5.1.1 ArQule Profile
5.1.2 ArQule Main Business
5.1.3 ArQule Adrenocortical Carcinoma Treatment Products, Services and Solutions
5.1.4 ArQule Adrenocortical Carcinoma Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 ArQule Recent Developments
5.2 EnGeneIC
5.2.1 EnGeneIC Profile
5.2.2 EnGeneIC Main Business
5.2.3 EnGeneIC Adrenocortical Carcinoma Treatment Products, Services and Solutions
5.2.4 EnGeneIC Adrenocortical Carcinoma Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 EnGeneIC Recent Developments
5.3 Exelixis
5.3.1 Exelixis Profile
5.3.2 Exelixis Main Business
5.3.3 Exelixis Adrenocortical Carcinoma Treatment Products, Services and Solutions
5.3.4 Exelixis Adrenocortical Carcinoma Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Merck Recent Developments
5.4 Merck
5.4.1 Merck Profile
5.4.2 Merck Main Business
5.4.3 Merck Adrenocortical Carcinoma Treatment Products, Services and Solutions
5.4.4 Merck Adrenocortical Carcinoma Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Merck Recent Developments
5.5 Millendo Therapeutics
5.5.1 Millendo Therapeutics Profile
5.5.2 Millendo Therapeutics Main Business
5.5.3 Millendo Therapeutics Adrenocortical Carcinoma Treatment Products, Services and Solutions
5.5.4 Millendo Therapeutics Adrenocortical Carcinoma Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Millendo Therapeutics Recent Developments
5.6 Orphagen Pharmaceuticals
5.6.1 Orphagen Pharmaceuticals Profile
5.6.2 Orphagen Pharmaceuticals Main Business
5.6.3 Orphagen Pharmaceuticals Adrenocortical Carcinoma Treatment Products, Services and Solutions
5.6.4 Orphagen Pharmaceuticals Adrenocortical Carcinoma Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Orphagen Pharmaceuticals Recent Developments
6 North America
6.1 North America Adrenocortical Carcinoma Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Adrenocortical Carcinoma Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Adrenocortical Carcinoma Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Adrenocortical Carcinoma Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Adrenocortical Carcinoma Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Adrenocortical Carcinoma Treatment Market Dynamics
11.1 Adrenocortical Carcinoma Treatment Industry Trends
11.2 Adrenocortical Carcinoma Treatment Market Drivers
11.3 Adrenocortical Carcinoma Treatment Market Challenges
11.4 Adrenocortical Carcinoma Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
